Swiss pharma major Roche has significantly expanded its artificial intelligence (AI) capabilities by deploying thousands of advanced GPUs from Nvidia, marking one of the largest AI infrastructure investments in the pharmaceutical sector.

The company has installed over 2,100 Nvidia Blackwell chips across its facilities in the United States and Europe, creating the industry’s largest GPU-powered computing network. This move is aimed at accelerating drug discovery, diagnostics development, and clinical research processes.

The enhanced computing capacity is expected to improve complex tasks such as data modelling, large-scale analytics, and clinical trial optimization. By leveraging AI at scale, Roche aims to significantly shorten drug development timelines while also reducing associated costs.

This expansion builds on Roche’s ongoing collaboration with Nvidia, which began in 2023, and reflects the growing reliance of global pharmaceutical companies on advanced technologies to stay competitive.

Company executives emphasized that speed is a critical factor in healthcare innovation, and AI-driven systems can help unlock faster insights and more efficient research outcomes.

The investment also aligns with broader industry trends, where AI—particularly emerging forms such as agentic AI—is expected to boost clinical development productivity by up to 35 Percent to 45 Percent over the next few years.

Overall, Roche’s move highlights the increasing convergence of pharmaceuticals and high-performance computing, positioning AI as a key driver of future healthcare breakthroughs.